Johnson & Johnson ROE 2010-2022 | JNJ

Current and historical return on equity (ROE) values for Johnson & Johnson (JNJ) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Johnson & Johnson ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-06-30 $18.37B $76.36B 24.87%
2022-03-31 $19.83B $74.71B 27.49%
2021-12-31 $20.88B $74.02B 29.86%
2021-09-30 $17.88B $70.27B 26.59%
2021-06-30 $17.77B $69.58B 27.01%
2021-03-31 $15.12B $65.83B 23.57%
2020-12-31 $14.71B $63.28B 23.35%
2020-09-30 $16.99B $64.47B 27.37%
2020-06-30 $15.19B $62.98B 25.10%
2020-03-31 $17.17B $61.29B 28.64%
2019-12-31 $15.12B $59.47B 25.47%
2019-09-30 $14.15B $58.21B 23.81%
2019-06-30 $16.33B $60.79B 26.76%
2019-03-31 $14.68B $58.96B 23.85%
2018-12-31 $15.30B $59.75B 24.42%
2018-09-30 $1.54B $64.63B 2.46%
2018-06-30 $1.37B $62.89B 2.11%
2018-03-31 $1.25B $63.26B 1.85%
2017-12-31 $1.30B $60.16B 1.88%
2017-09-30 $15.83B $73.98B 22.08%
2017-06-30 $16.34B $71.92B 22.89%
2017-03-31 $16.51B $70.34B 23.08%
2016-12-31 $16.54B $70.42B 22.95%
2016-09-30 $15.94B $72.77B 22.06%
2016-06-30 $15.03B $72.47B 20.88%
2016-03-31 $15.55B $72.65B 21.71%
2015-12-31 $15.41B $71.15B 21.88%
2015-09-30 $14.72B $71.55B 21.00%
2015-06-30 $16.11B $71.13B 22.58%
2015-03-31 $15.92B $67.88B 21.78%
2014-12-31 $16.32B $69.75B 21.69%
2014-09-30 $17.32B $76.59B 22.70%
2014-06-30 $15.55B $78.05B 20.84%
2014-03-31 $15.06B $76.58B 20.77%
2013-12-31 $13.83B $74.05B 19.73%
2013-09-30 $12.88B $69.80B 19.00%
2013-06-30 $12.87B $69.67B 19.41%
2013-03-31 $10.44B $66.86B 16.32%
2012-12-31 $10.85B $64.83B 17.34%
2012-09-30 $8.50B $63.76B 14.02%
2012-06-30 $8.74B $60.43B 14.54%
2012-03-31 $10.11B $61.37B 16.70%
2011-12-31 $9.67B $57.08B 16.08%
2011-09-30 $11.40B $61.53B 18.99%
2011-06-30 $11.61B $62.13B 19.69%
2011-03-31 $12.28B $59.86B 21.69%
2010-12-31 $13.33B $56.58B 24.28%
2010-09-30 $13.60B $57.29B 25.46%
2010-06-30 $13.53B $52.85B 26.17%
2010-03-31 $13.29B $52.91B 26.55%
2009-12-31 $12.27B $50.59B 25.69%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $435.655B $93.775B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $292.179B 37.05
AbbVie (ABBV) United States $249.673B 10.61
Pfizer (PFE) United States $245.989B 7.21
Merck (MRK) United States $218.318B 11.40
Novo Nordisk (NVO) Denmark $215.616B 28.44
Novartis AG (NVS) Switzerland $165.082B 12.17